Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Follow-Up Questions
Sequana Medical NV 'in CEO'su kimdir?
Ian Crosbie 2019 'den beri şirketle birlikte olan Sequana Medical NV 'in Chief Executive Officer 'ıdır.
SQNMF hissesinin fiyat performansı nasıl?
SQNMF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Sequana Medical NV için ana iş temaları veya sektörler nelerdir?
Sequana Medical NV Health Care endüstrisine ait ve sektör Health Care 'dir
Sequana Medical NV 'in piyasa değerlemesi nedir?
Sequana Medical NV 'in mevcut piyasa değerlemesi $NaN 'dir
Sequana Medical NV al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist Sequana Medical NV için analist derecelendirmeleri gerçekleştirdi, bunlar 4 güçlü al, 4 al, 2 tut, 0 sat ve 4 güçlü sat içermektedir
